follow recent run-up pt
follow increas recent week
believ current level impli appropri valu base
busi late-stag pipelin move ew
earn present next catalyst await
insight impact catalyst
downgrad ew current level impli valu jakafi sale upper
end long-term guidanc signific risk-adjust pipelin valu
risen throughout april believ current level impli
base busi jakafi sale jakavi olumi royalti cash
late-stag pipelin believ ruxolitinib cream
tafasitamab key area investor focu recal upgrad
ew ow earli april see note time
perceiv signific discount market valuat view
intrins valu embed within pipelin follow recent run-up
howev believ gap close difficult know
precis driven strength appear us
driven partial mileston achiev throughout april present
detail phiii data rux cream atop dermat initi phiii studi
evalu jakafi associ cytokin storm earli fda
approv fgfr inhibitor pemigatinib partial biotech sector strength
xbi april partial investor may view jakafi
therapi whose near-term sale trajectori rel insul
potenti relat disrupt therapeut may face
updat model pt move base follow
remov risk-adjust fgfr inhibitor pemigatinib
cholangiocarcinoma bile duct cancer follow fda approv
therapi also modifi pemigatinib price assumpt
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
base wac price disclosur provid follow approv
increas probability-of-success po assumpt ruxolitinib
cream atop dermat follow present
detail phiii data earli april found posit
correct patent cliff model jakafi reflect composit
matter patent expir decemb previou estim impli
earli patent cliff wherea model late drop-off
slightli decreas op ex assumpt account
reduc spend expect sg due potenti
earn present next catalyst believ key
near-term investor concern like impact management note
rux cream present earli april observ
commerci impact date jakafi result would expect
inform understand potenti impact jakafi sale
impact revenu guidanc howev believ earn could
provid insight potenti impact regulatori data-
relat catalyst anticip throughout remain focus
pdufa date tafasitamab r/r dlbcl initi jakafi life-cycl extens
data nda submiss rux cream ad phi data
tafasitamab dlbcl
encourag detail data present rux cream ad
jaka perform late-stag pipelineprogress drive risk/reward
deriv price target discount cash ow analysi factor explicit
revenu project use discount rate termin growth
equal-weight believ
current level impli adequ valu
royalti cash well appropri
risk-adjust valu late-stag
pipelin believ ruxolitinib cream
andtafasitamab key area focu
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
apr gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
jaka sale surpass upper rang
jaka sale surpass upper rang
perform ruxolitinib cream
perform ruxolitinib cream
tafasitamab success dlbcl
tafasitamab success dlbcl
jaka sale peak total
revenu ruxolitinib cream
gener peak sale
across vitiligo atop dermat
tafasitamab gener total contribut
guidanc coupl strong pipelin
guidanc coupl strong pipelin
realiz jaka sale
manag long-term guidanc
peak total revenu
approv strong uptak
ruxolitinib cream vitiligo atop
dermat aggreg peak sale
tafasitamab gener total
peak contribut
jaka sale manag
jaka sale manag
guidanc modest royalti revenu
guidanc modest royalti revenu
sale peak royalti revenu
peak iclusig sale
aggreg peak pipelin revenu
phiii data ruxolitinib steroid-refractori cgvhd
regulatori approv rux cream ad
phiii data vitiligo
clinic regulatori progress antibodi
data pemigatinib bladder cancer
detail jaka life cycl extens program
view explan region hierarchi
research highest favor quintil
greater pipelin realiz base case
project includ addit busi
long-term jaka sale perform
regulatori failurefor ruxolitinib cream ad
slow launch assum approv
clinic and/or regulatori failur tafasitamab
failur and/or minim success earlier-
stage program like pemigatinib
note suffici broker suppli
consensu data metric
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
mileston contract revenu
cost expens
product revenu incl definite-liv intang amort
chang fair valu acquisition-rel conting consider
total cost expens
incom loss oper
unreal loss long-term invest
expens relat senior note convers
incom loss provis incom tax
provis incom tax
cash equival
prepaid expens current asset
restrict cash invest
properti equip net
accru current liabil
accumul comprehens incom
total liabil stockhold equiti
flow oper activ
in-process research develop
expens relat senior note convers
unreal loss long-term invest
chang fair valu acquisition-rel conting consider
chang oper asset liabil
prepaid expens asset
accru liabil
net cash provid use oper activ
flow invest activ
acquisit busi net cash acquir
purchas long-term invest
purchas market secur
sale matur market secur
net cash use invest activ
flow financ activ
proce issuanc common stock stock plan
proce issuanc common stock net
paid connect senior note convers
payment conting consider
net cash provid financ activ
effect exchang rate cash cash equival restrict cash invest
net increas cash cash equival restrict cash invest
cash equival restrict cash invest begin period
cash equival restrict cash invest end period
